MRD is positioned to become a key component of decision making to determine the optimal treatment approach for transplant-eligible patients with multiple myeloma (MM), according to Kathleen A. Dorritie, MD, a hematologist-oncologist at the University of Pittsburgh Medical Center Hillman Cancer Center, who discussed the findings from several recent clinical trials in MM patients in a recent interview with OncLive®.
Most recently, results from the ongoing Forte trial presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December showed that patients who underwent stem cell transplantation achieved higher rates of MRD negativity at 1 year compared with those who did not undergo transplant, suggesting a correlation of MRD with survival.
Oliva S, Genuardi E, Petrucci MT, et al. Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial. Abstract 491 presented 12/6/2020. 62nd American Society of Hematology Annual Meeting and Exposition. https://ash.confex.com/ash/2020/webprogram/Paper137351.html